First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

British Journal of Cancer advance online publication, September 19 2017. doi:10.1038/bjc.2017.234

Authors: Riccardo Giampieri, Marco Puzzoni, Bruno Daniele, Daris Ferrari, Sara Lonardi, Alberto Zaniboni, Luigi Cavanna, Gerardo Rosati, Nicoletta Pella, Maria Giulia Zampino, Pietro Sozzi, Domenico Germano, Vittorina Zagonel, Carla Codecà, Michela Libertini, Roberto Labianca, Stefano Cascinu, The Italian Group for the Study of Gastrointestinal Cancer (GISCAD) & Mario Scartozzi

http://ift.tt/2xfrUhE